Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Labetuzumab govitecan |
Trade Name | |
Synonyms | IMMU-130 |
Drug Descriptions |
Labetuzumab govitecan (IMMU-130) is an antibody-drug conjugate comprised of CEACAM5 monoclonal antibody linked to the active metabolite of irinotecan (SN-38), which has potential antitumor activity (Journal of Clinical Oncology 2015 33:3_suppl, 625-625, PMID: 28817371, PMID: 30822636). |
DrugClasses | CEACAM5 Antibody 7 |
CAS Registry Number | 1469876-18-3 |
NCIT ID | C95710 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Labetuzumab govitecan | Labetuzumab govitecan | 0 | 0 |